- $3.83m
- $1.27m
- $9.93m
- 34
- 71
- 42
- 46
Annual income statement for iSpecimen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.3 | 8.18 | 11.1 | 10.4 | 9.93 |
Cost of Revenue | |||||
Gross Profit | 2.17 | 4.6 | 5.89 | 5.65 | 5.11 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.18 | 10.6 | 19.3 | 20.6 | 21.1 |
Operating Profit | -3.88 | -2.41 | -8.14 | -10.2 | -11.2 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.88 | -4.65 | -8.96 | -10.2 | -11.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.73 | -4.65 | -8.96 | -10.2 | -11.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.73 | -4.65 | -8.96 | -10.2 | -11.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.73 | -4.65 | -8.96 | -10.2 | -11.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.728 | -0.717 | -0.773 | -1.12 | -1.23 |
Dividends per Share |